Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflamm… Read more
Cytosorbents Crp (CTSO) - Total Assets
Latest total assets as of September 2025: $45.75 Million USD
Based on the latest financial reports, Cytosorbents Crp (CTSO) holds total assets worth $45.75 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cytosorbents Crp - Total Assets Trend (2004–2024)
This chart illustrates how Cytosorbents Crp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cytosorbents Crp - Asset Composition Analysis
Current Asset Composition (December 2024)
Cytosorbents Crp's total assets of $45.75 Million consist of 45.6% current assets and 54.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.9% |
| Accounts Receivable | $7.32 Million | 15.5% |
| Inventory | $2.73 Million | 5.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.75 Million | 7.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2024)
This chart illustrates how Cytosorbents Crp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytosorbents Crp's current assets represent 45.6% of total assets in 2024, an increase from 33.3% in 2004.
- Cash Position: Cash and equivalents constituted 6.9% of total assets in 2024, down from 33.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 15.5% of total assets.
Cytosorbents Crp Competitors by Total Assets
Key competitors of Cytosorbents Crp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Cytosorbents Crp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Cytosorbents Crp generates 0.75x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cytosorbents Crp is currently not profitable relative to its asset base.
Cytosorbents Crp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.11 | 1.97 | 8.12 |
| Quick Ratio | 1.71 | 1.58 | 7.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $11.20 Million | $ 8.17 Million | $ 72.30 Million |
Cytosorbents Crp - Advanced Valuation Insights
This section examines the relationship between Cytosorbents Crp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.05 |
| Latest Market Cap to Assets Ratio | 0.79 |
| Asset Growth Rate (YoY) | -11.1% |
| Total Assets | $47.37 Million |
| Market Capitalization | $37.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cytosorbents Crp's assets below their book value (0.79 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cytosorbents Crp's assets decreased by 11.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cytosorbents Crp (2004–2024)
The table below shows the annual total assets of Cytosorbents Crp from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $47.37 Million | -11.06% |
| 2023-12-31 | $53.26 Million | -15.77% |
| 2022-12-31 | $63.23 Million | -29.37% |
| 2021-12-31 | $89.52 Million | -0.48% |
| 2020-12-31 | $89.95 Million | +228.49% |
| 2019-12-31 | $27.38 Million | -16.38% |
| 2018-12-31 | $32.75 Million | +35.86% |
| 2017-12-31 | $24.10 Million | +148.65% |
| 2016-12-31 | $9.69 Million | -13.87% |
| 2015-12-31 | $11.25 Million | +32.89% |
| 2014-12-31 | $8.47 Million | +109.33% |
| 2013-12-31 | $4.05 Million | +21.15% |
| 2012-12-31 | $3.34 Million | +57.33% |
| 2011-12-31 | $2.12 Million | +17.14% |
| 2010-12-31 | $1.81 Million | -19.06% |
| 2009-12-31 | $2.24 Million | -33.91% |
| 2008-12-31 | $3.39 Million | +322.04% |
| 2007-12-31 | $802.57K | -76.70% |
| 2006-12-31 | $3.45 Million | +17991.84% |
| 2005-12-31 | $19.04K | -36.53% |
| 2004-12-31 | $30.00K | -- |